Clinical trials: Diabetes, Type 1
Type 2 Diabetes Mellitus
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A Phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT02548585
- Testing
- MEDI0382
- Where
- 11 sites in Germany
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Diabetes Type 1
InPen User Experience
The purpose of this study is to evaluate the user experience of InPen™ with InPen™ Diabetes Management App and Guardian 4 system in adult patients with type 1 diabetes for the design of a future pivotal study.
- Trial name
- NCT05029271
- Testing
- InPen with Guardian 4 System
- Where
- 3 sites in Sweden
- Volunteers
- 34 people
- Sponsor
- Medtronic MiniMed, Inc.
Wolfram Syndrome
AMX0035 in Adult Patients With Wolfram Syndrome
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
- Trial name
- NCT05676034
- Testing
- AMX0035
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Type 1 Diabetes Mellitus
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus. There are 2 parts to this study.
- Trial name
- NCT03465878
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Canada, Germany
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
A premarket, international multicenter, prospective, open label, adaptive, randomized controlled study. The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed™640G and SmartGuard™in preventing…
- Trial name
- SMILE (NCT02733991)
- Testing
- MiniMed™640G and Suspend before low, MiniMed™640G
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 153 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with…
- Trial name
- NCT00612040
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 33 sites in United States, Australia and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 620G and 640G Insulin Pumps
This six center international study will include two United Kingdom National Health Service centers, two centers in Melbourne, Australia and one center each in Denmark and Spain.
- Trial name
- NCT01726621
- Testing
- Medtronic MiniMed 620G or 640G Insulin Pump
- Where
- 6 sites in Australia, Denmark and 2 more
- Volunteers
- 55 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1
Prospective Decision Impact Trial of KidneyIntelX
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
- Trial name
- NCT04960514
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetes Mellitus, Type 1
Mylan Insulin Glargine Study
The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1…
- Trial name
- NCT03376789
- Testing
- MYL-1501D product using manufacture process V, MYL-1501D product using manufacture process VI
- Where
- 38 sites in United States
- Volunteers
- 219 people
- Sponsor
- Mylan Inc.
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1, Healthy Volunteers
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
This study is investigating the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentrations in the blood and its effect on blood sugar for the treatment of diabetes.
- Trial name
- NCT03965013
- Testing
- NNC0268-0965, insulin glargine
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease
The purpose of this study is to evaluate the cardiovascular effects of pioglitazone, once daily (QD), versus glyburide when administered to patients with type 2 diabetes mellitus and mild cardiac disease.
- Trial name
- NCT00521742
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 300 people
- Sponsor
- Takeda
Type 1 Diabetes
Evaluating the Occurrence of DKA in People With Type I Diabetes
This study will evaluate the occurrences of Diabetes-related Ketoacidosis (DKA) in adult and pediatric individuals living with Type I diabetes while managing diabetes with Abbott's Continuous Monitoring Systems.
- Trial name
- NCT07739342
- Testing
- Abbott Continuous Dual Glucose Ketone Monitoring System
- Where
- 7 sites in New Zealand
- Volunteers
- 1,200 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus
A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China
The purpose of this study is to demonstrate the performance and safety of the Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
- Trial name
- NCT03417466
- Testing
- Enlite 1 connected to iPro2 recorder
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
A randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus (T1DM)
- Trial name
- NCT03895697
- Testing
- dasiglucagon
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Zealand Pharma
Diabetes Mellitus, Type 1, Diabetic Polyneuropathy
Effect of C-Peptide on Diabetic Peripheral Neuropathy
The aim of the study is to investigate the effect of C-peptide administration on nerve function in patients with type 1 diabetes and peripheral sensory neuropathy.
- Trial name
- NCT00278980
- Testing
- C-peptide
- Where
- Sweden
- Volunteers
- 180 people
- Sponsor
- Creative Peptides Sweden Inc.
Type 1 Diabetes
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®
This US study will evaluate the safety and effectiveness of utilizing insulin Lyumjev® lispro-aabc in the MiniMed™ 780G System in Type 1 adult and pediatric subjects in a home setting to support product and system labeling.
- Trial name
- NCT05325294
- Testing
- MiniMed 780G System
- Where
- 19 sites in United States
- Volunteers
- 244 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to test for bioequivalence between two formulations of insulin degludec/insulin aspart (IDegAsp) to see if the efficacy and safety obtained with formulation 1 can be…
- Trial name
- NCT01455142
- Testing
- insulin degludec/insulin aspart
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
This trial is conducted in Europe. The aim of the trial is to compare two methods of injection in basal-bolus insulin regimen in children with type 1 diabetes with insulin detemir associated with insulin aspart given twice daily…
- Trial name
- MIXING (NCT00542620)
- Testing
- insulin detemir, insulin aspart
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.